Anti-angiogenic strategies will be a revolution in lymphoma?
Paydas
Semra
S
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000639:trends; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D042583:Lymphangiogenesis / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042582:Vascular Endothelial Growth Factor C